Evidence map›Paper›PMID 42182836›Full record

ArticleOpen forum infectious diseases2026

Randomized Phase 3 Comparison of a 2-Dose and 3-Dose Regimen of a Detoxified Toxin A/B

Gretchen Crook, Erik Lamberth, Stephen P Lockhart, Francine Lowry, Haiying Zhang, Yahong Peng, Kenneth Koury, Warren V Kalina, Michael W Pride, Annaliesa S Anderson and 2 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gretchen CrookARC Clinical Research, Austin, Texas, USA.
Erik LamberthVaccine Research & Development, Pfizer Inc, Collegeville, Pennsylvania, USA.
Stephen P LockhartVaccine Research & Development, Pfizer Ltd, Marlow, UK.ORCID https://orcid.org/0000-0002-0805-2193
Francine LowryVaccine Research & Development, Pfizer Inc, Collegeville, Pennsylvania, USA.
Haiying ZhangVaccine Research & Development, Pfizer Inc, Collegeville, Pennsylvania, USA.
Yahong PengVaccine Research & Development, Pfizer Inc, Collegeville, Pennsylvania, USA.
Kenneth KouryVaccine Research & Development, Pfizer Inc, Pearl River, New York, USA.
Warren V KalinaVaccine Research & Development, Pfizer Inc, Pearl River, New York, USA.
Michael W PrideVaccine Research & Development, Pfizer Inc, Pearl River, New York, USA.ORCID https://orcid.org/0000-0001-7104-2433
Annaliesa S AndersonVaccine Research & Development, Pfizer Inc, Pearl River, New York, USA.
William C GruberVaccine Research & Development, Pfizer Inc, Pearl River, New York, USA.ORCID https://orcid.org/0000-0002-6518-4547
Nicholas KitchinVaccine Research & Development, Pfizer Ltd, Marlow, UK.ORCID https://orcid.org/0000-0002-1808-3380

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This phase 3 trial compared immunogenicity and safety of 2-dose versus 3-dose PF-06425090

Indexed as

C difficiledosing regimenimmunogenicitysafetyvaccine

Identifiers

PMID42182836
PMCPMC13192345

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.